| 包装 | 价格(元) |
| 500 µg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 别名 | YM905-d5 |
| Canonical SMILES | O=C(O[C@H]1CN2CCC1CC2)N3[C@@H](C4=C([2H])C([2H])=C([2H])C([2H])=C4[2H])C5=CC=CC=C5CC3.OC(CCC(O)=O)=O |
| 分子式 | C23H21D5N2O2·C4H6O4 |
| 分子量 | 485.6 |
| 溶解度 | DMSO: soluble,Methanol: soluble,Water: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | carbamoylcholine Solifenacin-d5is intended for use as an internal standard for the quantification of solifenacin by GC- or LC-MS. Solifenacin is a competitive antagonist of M1, M2, and M3muscarinic acetylcholine receptors (Kis = 25, 125, and 10 nM, respectively, for the human receptors).1It inhibits calcium mobilization induced by carbamoylcholine in isolated guinea pig detrusor muscle cells (Ki= 4 nM).2Solifenacin inhibits carbachol-induced contraction of isolated guinea pig urinary bladder smooth muscle.In vivo, solifenacin (0.03-1 mg/kg) inhibits carbachol-induced increases in urinary bladder pressure in anesthetized rats. Formulations containing solifenacin have been used in the treatment of overactive bladder. 1.Hegde, S.S.Muscarinic receptors in the bladder: From basic research to therapeuticsBr. J. Pharmacol.147(2)S80-S87(2006) 2.Ikeda, K., Koboyashi, S., Suzuki, M., et al.M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary glandNaunyn Schmiedebergs Arch. Pharmacol.366(2)97-103(2002) |
m.cnreagent.com